| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The molecular targets of NI-1-Br are not biological targets, as the compound is a luminescent agent used in materials science and biochemical research rather than a pharmaceutical agent. In luminescence applications, NI-1-Br functions as a fluorophore or phosphor that absorbs light at a specific wavelength and emits light at a longer wavelength. The compound's photophysical properties, including its absorption and emission spectra, quantum yield, and lifetime, determine its utility in various applications. In biochemical research, NI-1-Br may be used as a fluorescent probe for labeling or sensing applications, or as a component of luminescent materials for optoelectronic devices. The compound does not have specific biological targets and is not designed to interact with enzymes, receptors, or other biomolecules in a targeted manner. Its primary utility is in the development of luminescent materials and probes for research applications.
|
|---|---|
| ln Vitro |
In vitro activity of NI-1-Br is characterized by its photophysical properties rather than biological activity. In materials science assays, NI-1-Br is evaluated for its absorption and emission spectra, fluorescence quantum yield, and fluorescence lifetime. The compound's photophysical properties are typically measured using UV-Vis and fluorescence spectroscopy. The compound's absorption maximum is expected in the UV-visible range (300-450 nm), and its emission maximum is expected in the visible range (400-600 nm), depending on the solvent and environment. The compound's quantum yield and lifetime are measured using absolute quantum yield measurements and time-resolved fluorescence spectroscopy. In biochemical research, NI-1-Br may be evaluated for its utility as a fluorescent probe, including its brightness, photostability, and sensitivity to environmental factors such as pH, polarity, and viscosity. Specific biological activities, such as IC50 values against specific targets, are not applicable for this compound.
|
| ln Vivo |
In vivo activity of NI-1-Br is not relevant, as the compound is a luminescent agent used in research and is not intended for administration to living organisms. The compound is not developed as a therapeutic agent and does not have pharmacological effects in vivo. Its use in biological research may include the development of luminescent probes for in vivo imaging, where NI-1-Br would be used as a component of a probe that targets specific biomarkers. However, the compound itself is not tested for in vivo efficacy. Any potential exposure to NI-1-Br in research settings would be related to handling during experiments, and appropriate safety precautions should be taken. The compound is classified as a biochemical reagent and is not intended for human therapeutic or diagnostic applications.
|
| Enzyme Assay |
For in vitro photophysical characterization assays with NI-1-Br, the following protocol is used: NI-1-Br is dissolved in an appropriate solvent (e.g., DMSO, dichloromethane, or ethanol) at a concentration of 1-10 μM. The UV-Vis absorption spectrum is recorded using a spectrophotometer, scanning from 200 to 800 nm. The fluorescence emission spectrum is recorded using a fluorescence spectrophotometer, with excitation at the absorption maximum and emission scanned from the excitation wavelength to 800 nm. The fluorescence quantum yield is measured using a relative method with a standard fluorophore (e.g., fluorescein in 0.1 M NaOH, quantum yield 0.92) or an absolute method using an integrating sphere. The fluorescence lifetime is measured using time-correlated single photon counting (TCSPC) or a streak camera. The compound's solvatochromic properties are assessed by measuring the absorption and emission spectra in solvents of different polarity (e.g., hexane, toluene, dichloromethane, acetonitrile, ethanol, water). The compound's photostability is assessed by measuring the fluorescence intensity over time under continuous irradiation.
|
| Cell Assay |
For in vitro cell-based imaging assays with NI-1-Br, the following typical protocol is used: Mammalian cells (e.g., HeLa, HEK293, or primary cells) are cultured in DMEM with 10% FBS and antibiotics at 37°C in 5% CO₂. Cells are seeded on coverslips or in 96-well plates and allowed to adhere overnight. NI-1-Br is dissolved in DMSO and diluted in culture medium to final concentrations of 0.1-10 μM (final DMSO ≤ 0.1%). Cells are incubated with the compound for 30 minutes to 24 hours. Cells are washed with PBS to remove unbound compound. For fluorescence microscopy, cells are fixed with 4% paraformaldehyde and mounted on slides. Images are acquired using a fluorescence microscope with appropriate filter sets (e.g., excitation 350-400 nm, emission 420-500 nm). For live-cell imaging, cells are maintained at 37°C during imaging. For flow cytometry analysis, cells are trypsinized, resuspended in PBS, and analyzed on a flow cytometer with appropriate laser and emission filter settings. For assessment of cellular uptake, cells are lysed and the fluorescence intensity is measured using a microplate reader.
|
| Additional Infomation |
NI-1-Br (CAS# 1771756-32-1) is a luminescent agent and biochemical reagent with a molecular formula of C23H15BrN2 and a molecular weight of 399.28 g/mol. It is also known as 2-(4-bromophenyl)-3-phenyl-3H-naphth[1,2-d]imidazole. Future research could focus on developing new luminescent materials based on the naphthimidazole scaffold, investigating the compound's photophysical properties for imaging and sensing applications, and exploring its utility in optoelectronic devices and biological probes.
|
| Molecular Formula |
C23H15BRN2
|
|---|---|
| Molecular Weight |
399.2826
|
| Exact Mass |
398.04
|
| Elemental Analysis |
C, 69.19 H, 3.79 Br, 20.01 N, 7.02
|
| CAS # |
1771756-32-1
|
| PubChem CID |
155908177
|
| Appearance |
Solid powder
|
| LogP |
6.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)N2C3=C(C4=CC=CC=C4C=C3)N=C2C5=CC=C(C=C5)Br
|
| InChi Key |
KLHZNVLXKGCRBF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H15BrN2/c24-18-13-10-17(11-14-18)23-25-22-20-9-5-4-6-16(20)12-15-21(22)26(23)19-7-2-1-3-8-19/h1-15H
|
| Chemical Name |
2-(4-bromophenyl)-3-phenylbenzo[e]benzimidazole
|
| Synonyms |
NI-1-Br; KUN56321; KUN-56321; KUN-56321;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5045 mL | 12.5225 mL | 25.0451 mL | |
| 5 mM | 0.5009 mL | 2.5045 mL | 5.0090 mL | |
| 10 mM | 0.2505 mL | 1.2523 mL | 2.5045 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
